Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆Y. Di Filippo, Henri Montaudié, A Stephan et al.|Annals of Oncology|2020Cited by 30
Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort StudySandra Huynh, Julie Delyon, Laurent Mortier et al.|Cancers|2020Cited by 21
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National CohortManon Girod, O. Dereure, Stéphane Dalle et al.|JCO Precision Oncology|2022Cited by 14
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)David Russo, Lise Boussemart, Stéphane Dalle et al.|Frontiers in Oncology|2023Cited by 10
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohortClémentine Carlet, Charlée Nardin, Stéphane Dalle et al.|Journal of the American Academy of Dermatology|2021Cited by 9